{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:46:53Z","timestamp":1753890413907,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hereditary angioedema (HAE) is a life-threatening condition characterized by repeated asymmetric cutaneous and mucosal edema. It is a rare autosomal dominant genetic disease with a mortality rate of 8.6%. Family survey of HAE in China is seldom reported since it is still under recognized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>We reported two cases of HAE and a family survey conducted in Hebei Province, China. The proband was a woman who had edema for over 7 years. She was diagnosed with type I HAE in her 50s after a life-threatening asphyxia attack. Her elder brother was initially diagnosed with mild symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Two diagnosed and three suspected patients were identified in our family survey. Family surveys are important method for identifying asymptomatic patients and preventing attacks. It is valuable for rescuing people from sudden death, particularly from asphyxia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1587904","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:23:51Z","timestamp":1748841831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Two cases of hereditary angioedema in a Chinese family"],"prefix":"10.3389","volume":"6","author":[{"given":"Yuanli","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manli","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinluan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-024-03265-z","article-title":"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review","volume":"19","author":"Guan","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.waojou.2021.100620","article-title":"The prevalence of hereditary angioedema in a Chinese cohort with decreased complement 4 levels","volume":"15","author":"Cui","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100627","DOI":"10.1016\/j.waojou.2022.100627","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"15","author":"Maurer","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1684\/ejd.2020.3758","article-title":"Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey","volume":"30","author":"Liu","year":"","journal-title":"Eur J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.iac.2024.03.011","article-title":"Contact system activation and Bradykinin generation in angioedema: laboratory assessment and biomarker utilization","volume":"44","author":"Christiansen","year":"2024","journal-title":"Immunol Allergy Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","first-page":"152790","DOI":"10.1016\/j.imbio.2024.152790","article-title":"Transmission patterns of C1-INH deficiency hereditary angioedema favors a wild-type male offspring: our experience at Chandigarh, India","volume":"229","author":"Machhua","year":"2024","journal-title":"Immunobiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1406953","DOI":"10.3389\/fcvm.2024.1406953","article-title":"Plasminogen missense variants and their involvement in cardiovascular and inflammatory disease","volume":"11","author":"Brito-Robinson","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/blood-2018-06-860270","article-title":"A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain","volume":"133","author":"Ivanov","year":"2019","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary angioedema: diagnosis, clinical implications, and pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2500\/aap.2020.41.190021","article-title":"Manufacturing of plasma-derived C1-inhibitor concentrate for treatment of patients with hereditary angioedema","volume":"41","author":"Simon","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa0905079","article-title":"Ecallantide for the treatment of acute attacks in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/17512433.2016.1182425","article-title":"Icatibant as acute treatment for hereditary angioedema in adults","volume":"9","author":"Farkas","year":"2016","journal-title":"Expet Rev Clin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e9669","DOI":"10.7759\/cureus.9669","article-title":"Novel use of fresh frozen plasma in treating hereditary angioedema: a success story from Pakistan","volume":"12","author":"Sabeen Ahmed","year":"2020","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jaip.2019.08.011","article-title":"Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema","volume":"8","author":"Valerieva","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1177\/0897190019857407","article-title":"Successful long-term prophylactic treatment with subcutaneous C1 esterase inhibitor in a patient with hereditary angioedema","volume":"33","author":"Hahn","year":"2020","journal-title":"J Pharm Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1016\/j.jaip.2021.04.072","article-title":"Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study","volume":"9","author":"Buttgereit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.jaip.2021.03.057","article-title":"Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2)","volume":"9","author":"Wedner","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2362.2010.02402.x","article-title":"Long-term efficacy of danazol treatment in hereditary angioedema","volume":"41","author":"Fust","year":"2011","journal-title":"Eur J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jaci.2011.11.025","article-title":"International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency","volume":"129","author":"Caballero","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"134097","DOI":"10.1016\/j.ijbiomac.2024.134097","article-title":"A comprehensive review on the current status of CRISPR based clinical trials for rare diseases","volume":"277","author":"Badwal","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000541242","article-title":"Initial experience of long-term prophylaxis with lanadelumab for hereditary angioedema in China: a clinical observation study on six patients","volume":"186","author":"Yao","year":"2025","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1587904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T05:23:52Z","timestamp":1748841832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1587904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":22,"alternative-id":["10.3389\/falgy.2025.1587904"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1587904","relation":{},"ISSN":["2673-6101"],"issn-type":[{"type":"electronic","value":"2673-6101"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"article-number":"1587904"}}